Compare XBIT & SYPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XBIT | SYPR |
|---|---|---|
| Founded | 2005 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.4M | 72.5M |
| IPO Year | 2015 | 1996 |
| Metric | XBIT | SYPR |
|---|---|---|
| Price | $2.35 | $2.56 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 26.1K | ★ 142.2K |
| Earning Date | 05-08-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $82,294,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.09 | $1.79 |
| 52 Week High | $3.61 | $4.74 |
| Indicator | XBIT | SYPR |
|---|---|---|
| Relative Strength Index (RSI) | 39.19 | 35.11 |
| Support Level | $2.35 | $2.01 |
| Resistance Level | $2.41 | $2.72 |
| Average True Range (ATR) | 0.06 | 0.32 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 13.79 | 4.24 |
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
Sypris Solutions Inc provides products and engineering, design, and manufacturing services for a variety of critical infrastructure sectors, including energy, space, communications, defense, transport, chemical, and water. The company operates in two segments, Sypris Technologies and Sypris Electronics. Sypris Technologies segment includes the sale of forged, machined, welded and heat-treated steel components for heavy commercial vehicle and high-pressure energy pipeline applications, whereas the Sypris Electronics segment includes revenue from circuit card and box build manufacturing, high reliability manufacturing and systems assembly and integration, for aerospace and defense, communications and space applications. The majority of revenue is derived from the Sypris Electronics segment.